Display options
Share it on

J Clin Aesthet Dermatol. 2015 Aug;8(8):16-21.

Long-term Multi-product Facial Regimen in Subjects with Moderate-to-severe Photodamage and Hyperpigmentation.

The Journal of clinical and aesthetic dermatology

James H Herndon, Elizabeth T Makino, Lily I Jiang, Thomas J Stephens, Rahul C Mehta

Affiliations

  1. Thomas J. Stephens & Associates, Richardson, Texas.
  2. SkinMedica, an Allergan Company, Carlsbad, California.

PMID: 26345199 PMCID: PMC4557846

Abstract

BACKGROUND: Photoaged skin is primarily a result of chronic sun exposure. Irregular pigmentation and wrinkling are common clinical manifestations. Monotherapy with retinoids, growth factors, and skin lighteners have proven beneficial. However, long-term treatment with a multi-product facial regimen has not been assessed.

OBJECTIVES: This single-center clinical trial was conducted to assess the efficacy and tolerance of a topical multi-product regimen when used by subjects with moderate-to-severe photodamage and hyperpigmentation on the face over a course of 24 weeks.

METHODS: Subjects were supplied with a six-product regimen to use on their face (cleanser, growth factor serum, skin brightener, moisturizer, retinol, and sunscreen). Products were used according to specific application instructions. Clinical grading and tolerability assessments were performed at baseline and at follow-up visits at Weeks 4,8,12,18, and 24. Standardized digital photographs were taken and self-assessment questionnaires were conducted. Image analysis for skin-tone evenness and brightness was also conducted.

RESULTS: Seventy-two subjects completed the 24-week study. All clinical efficacy parameters showed statistically significant improvements over baseline at all visits. Plateau effects for these improvements were not seen at 24 weeks. The facial regimen was well-tolerated. Subject questionnaires showed the regimen was highly rated at all visits.

CONCLUSION: This six-product, comprehensive facial regimen was shown to be clinically effective and well-tolerated for the treatment of moderate-to-severe photodamage and hyperpigmentation over 24 weeks. Additional benefits may occur with continued use.

References

  1. J Drugs Dermatol. 2012 Dec;11(12 ):1478-82 - PubMed
  2. J Cosmet Dermatol. 2008 Sep;7(3):164-8 - PubMed
  3. J Cosmet Dermatol. 2011 Dec;10 (4):253-9 - PubMed
  4. Br J Dermatol. 1990 Apr;122 Suppl 35:21-8 - PubMed
  5. J Drugs Dermatol. 2012 Jan;11(1):64-9 - PubMed
  6. J Am Acad Dermatol. 1990 Jan;22(1):1-15 - PubMed
  7. J Drugs Dermatol. 2007 Feb;6(2):197-201 - PubMed
  8. Dermatol Ther. 2006 Sep-Oct;19(5):280-8 - PubMed
  9. J Cosmet Laser Ther. 2010 Feb;12(1):14-20 - PubMed
  10. Arch Dermatol. 1992 Mar;128(3):347-51 - PubMed
  11. J Am Acad Dermatol. 1989 Sep;21(3 Pt 2):610-3 - PubMed
  12. J Drugs Dermatol. 2008 Sep;7(9):864-71 - PubMed
  13. Arch Dermatol. 2002 Nov;138(11):1462-70 - PubMed
  14. J Am Acad Dermatol. 1986 Oct;15(4 Pt 2):836-59 - PubMed
  15. J Cosmet Dermatol. 2010 Jun;9(2):89-95 - PubMed
  16. J Cosmet Dermatol. 2013 Mar;12 (1):12-7 - PubMed
  17. Br J Dermatol. 1990 Jan;122(1):91-8 - PubMed
  18. Dermatol Surg. 2006 May;32(5):618-25 - PubMed
  19. Arch Dermatol. 1997 Oct;133(10):1296-9 - PubMed

Publication Types